title: Immunophenotypic aberrations, DNA content, and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies.
abstract: We describe the immunophenotypic and gross DNA defects in 55 patients with myeloma and 50 patients with monoclonal gammopathy and review the literature on this subject (MedLine, 1994-2000). Our data confirmed previous reports indicating that in myeloma nearly all marrow plasma cells are abnormal (98.7 +/- 8.1%). In monoclonal gammopathy the fraction of abnormal plasma cells was 35.0 +/- 32.8%. In both myeloma and monoclonal gammopathy, the most frequent aberrant phenotypic features consisted of absence of expression of CD19, strong expression of CD56, and decreased intensity of expression of CD38; aberrant expression of CD10, CD20, CD22, or CD28 was observed in less than one-third of myeloma cases. The vast majority of cases had two or more phenotypic aberrations. In the DNA studies, 7% of myeloma cases were biclonal and 93% of cases were monoclonal. In those studies with only one plasma cell mitotic cycle, 37% had normal DNA content and 63% were aneuploid (hyperploid, 61%; hypoploid, 2%). The mean percentages of plasma cells in S- and G2M phases were 4.9 +/- 8.5 and 4.4 +/- 6.9%, respectively. Thirty-eight percent of cases had more than 3% of plasma cells in S phase. In monoclonal gammopathy, the DNA index of abnormal plasma cells ranged from 0.89 to 1.30 and the percentage of diploid (31%) and aneuploid (69%) cases was not different from the results found in myeloma. The differences in percentage of abnormal plasma cells in S- (7.4 +/- 8.6%) and G2M-phases (2.4 +/- 1.7%) in patients with monoclonal gammopathy were not statistically significant.
authors.affiliation: Service of Clinical Hematology, Hospital Geral de Santo António, Rua D Manual II, s/n, 4050 Porto, Portugal. m.lima@ip.pt
authors.forename: M
authors.initials: M
authors.lastname: Lima
authors.forename: M dos A
authors.initials: Mdos A
authors.lastname: Teixeira
authors.forename: S
authors.initials: S
authors.lastname: Fonseca
authors.forename: C
authors.initials: C
authors.lastname: Gonçalves
authors.forename: M
authors.initials: M
authors.lastname: Guerra
authors.forename: M L
authors.initials: ML
authors.lastname: Queirós
authors.forename: A H
authors.initials: AH
authors.lastname: Santos
authors.forename: A
authors.initials: A
authors.lastname: Coutinho
authors.forename: L
authors.initials: L
authors.lastname: Pinho
authors.forename: L
authors.initials: L
authors.lastname: Marques
authors.forename: M
authors.initials: M
authors.lastname: Cunha
authors.forename: P
authors.initials: P
authors.lastname: Ribeiro
authors.forename: L
authors.initials: L
authors.lastname: Xavier
authors.forename: H
authors.initials: H
authors.lastname: Vieira
authors.forename: P
authors.initials: P
authors.lastname: Pinto
authors.forename: B
authors.initials: B
authors.lastname: Justiça
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002453:Cell Cycle; D004247:DNA / Q000032:analysis*; D003937:Diagnosis, Differential; D018450:Disease Progression; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping / Q000592:standards*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000473:pathology; D010265:Paraproteinemias / Q000175:diagnosis* / Q000473:pathology; D010950:Plasma Cells / Q000737:chemistry / Q000473:pathology*
chemical_list: D004247:DNA